WASHINGTON – “Hallmarks and enabling characteristics should be not special cases, but rather reasonably broad across the spectrum of human cancers,” Robert Weinberg told BioWorld Today.
WASHINGTON – Researchers at Yale University have received conditional approval for a clinical trial that will test whether isocitrate dehydrogenase (IDH)-mutated tumors might respond better to poly-ADP ribose polymerase (PARP) inhibitors than to IDH inhibitors.
WASHINGTON – Data from the Heracles and SUMMIT trials presented at the 2017 annual meeting of the American Association for Cancer Research confirmed that HER2-targeting drugs, which were originally developed for breast cancer, can be useful both for treating other tumor types and for patients whose HER2 gene is mutated but who do not overexpress HER2 protein.
WASHINGTON – As scientists gathered at the 2017 meeting of the American Association for Cancer Research (AACR) to learn about the latest advances in cancer research, one of the questions was how much of that research would hold up to attempts to reproduce it.
One of the challenges of developing a dengue virus vaccine is that there are four different variants of the virus, and antibodies that kill one subtype can actually exacerbate infection with another subtype. The process is known as antibody-dependent enhancement (ADE).
Edward Teller's quote that "the science of today is the technology of tomorrow" got empirical support by work published in the March 31, 2017, issue of Science.
The small molecule PF-06446846 selectively blocked the translation of PCSK9 messenger RNA, showing that the ribosome can be targeted in a protein-specific manner.
Inhibiting the enzyme glyoxalase 1 (Glo-1), which was originally identified as a metabolic housekeeping enzyme but also affects anxiety, relieved symptoms of depression more rapidly than Prozac (fluoxetine, Eli Lilly and Co.) in several different animal models.
Activating Sirtuin1 may be a host-directed strategy to fight tuberculosis infection, researchers from the Singapore Agency for Science, Technology and Research have reported.
